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Individuals who have colorectal cancer (CRC) or endometrial cancer (EC) displaying loss of
immunohistochemical (IHC) staining of one or more mismatch repair (MMR) proteins
without a causative germline mutation are said to have unexplained mismatch repair
deficiency (UMMRD, also known as mutation-negative Lynch syndrome). Comprehensive
genetic testing that could potentially further clarify Lynch syndrome (LS) carrier status is
essential to provide tailored screening guidelines to affected individuals and their family
members; however, patient understanding of the potential impact of updated genetic testing
for LS is unclear. This study aimed to evaluate the interest in and perceived impact of
updated genetic testing among individuals with UMMRD at a tertiary academic center. A
survey evaluating interest in updated genetic testing was mailed to 98 potential participants,
and an electronic health record review was completed for the 31 individuals who returned the
survey. Results indicate that this population is highly interested in updated genetic testing,
and their perceived impact is primarily for family members to have appropriate testing and
screening options. Updated risk assessment and genetic counseling, along with a discussion
of the benefits and limitations of genetic testing, is essential as the understanding of potential
causes of UMMRD evolves. Updated genetic counseling may allow patients with UMMRD
to better understand the interpretation of their tumor and germline testing, as well as the
impact of comprehensive genetic testing for themselves and their family members.
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INTRODUCTION
Lynch syndrome (LS) is a hereditary cancer syndrome affecting 1 in 440 individuals
(1), and is characterized by an increased risk to develop colorectal cancer (CRC) and
endometrial cancer (EC), as well as ovarian, stomach, small intestine, pancreatic, urinary
tract, and brain cancers and sebaceous neoplasms (2). LS is caused by a heterozygous
pathogenic variant in one of four genes involved in the DNA mismatch repair (MMR)
system: MLH1, MSH2, MSH6, and PMS2. Additionally, deletions of the EPCAM gene cause
hypermethylation of the MSH2 promoter region and are also associated with LS (3).
CRC and EC in individuals with LS typically display high levels of microsatellite
instability (MSI-H) and/or show loss of immunohistochemical (IHC) staining of one or more
MMR proteins, most frequently corresponding with the underlying germline mutation. If a
CRC or EC presents with loss of function of the DNA MMR system, genetic testing is
recommended to determine if there is an underlying germline mutation causing LS. In most
cases when MLH1 and PMS2 proteins are absent, the loss of staining can be attributed to
sporadic causes such as somatic methylation of the MLH1 promoter (4) or BRAF mutations
in CRC only (5). The presence of either of these molecular events is most consistent with
sporadic cancer rather than LS.
In approximately 2-4% of patients with CRC, IHC staining indicates MMR protein
loss, but genetic testing does not detect a germline mutation (6, 7). This situation is known as
unexplained mismatch repair deficiency (UMMRD), and individuals are said to have Lynchlike syndrome or mutation-negative Lynch syndrome (8). Recent studies have shown that
biallelic somatic mutations explain the loss of protein staining in 45-69% of individuals with
UMMRD (6, 9). However, the etiology continues to be unknown for the remaining 31-55%
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of individuals with MMR deficiency. Some of these cases of UMMRD may be caused by an
underlying germline pathogenic variant that was not detected by the original genetic testing.
The suspicion for a previously undetected germline mutation is especially high for patients
meeting Amsterdam criteria for the detection of individuals likely to have LS (10).
Traditional genetic testing for LS, especially prior to the advent of next-generation
sequencing (NGS) panel testing, was based on the pattern of protein loss on IHC staining
(i.e., MSH2 genetic testing for absence of MSH2/MSH6 protein staining). However, this
strategy can fail to detect an underlying germline mutation for several reasons. First,
sequencing and deletion/duplication analysis of MMR genes may not detect the causative
pathogenic variant. For example, the MSH2 inversion of exons 1-7 causes a proportion of LS
cases that have MSH2/MSH6 loss of staining upon IHC analysis, but these inversions cannot
be identified on traditional gene sequencing or deletion/duplication analysis alone; this was
only recently identified and therefore not previously tested (11). Second, IHC analysis may
indicate a pair of missing proteins. If only one of the corresponding genes is analyzed, or if a
pathogenic variant is present in one of the other MMR genes, a germline mutation may be
missed. Third, IHC analysis may be false-normal, indicating that staining is intact while the
tumor is, in fact MMR deficient (12). For these reasons, as well as decreased cost of testing
multiple genes via NGS panel testing, patients suspected to have LS based on tumor testing
are now frequently offered sequencing and deletion/duplication analysis of all LS-associated
genes, as well as MSH2 inversion analysis.
Due to the high expected number of patients with UMMRD who are expected to have
biallelic somatic mutations, comprehensive germline genetic testing is not expected to
identify an underlying germline mutation in many cases. It is possible that future tests may
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have a higher yield or be able to definitively determine if an individual with UMMRD has
LS. For example, identification of biallelic somatic mutations on paired germline/tumor
testing may suggest a sporadic etiology for patients who have UMMRD. However,
comprehensive evaluation of individuals with UMMRD for underlying germline mutations is
essential to provide appropriate risk assessment and screening recommendations. There is no
difference between the median age of cancer diagnosis of an individual with LS as compared
to one with UMMRD (7). However, the standardized incidence ratio for family members of
individuals with UMMRD to develop CRC is 2.12 as compared to 6.04 for family members
of individuals with an identified germline mutation and 0.48 for family members with
sporadic CRC. This suggests that UMMRD is a heterogeneous group composed of some
patients who have LS and others who have sporadic cancers. Determining which individuals
have LS and which have sporadic cancers allows for appropriate screening tailored to the risk
of cancer in each group, as well as appropriate testing for the identified familial variant in
individuals determined to have LS (7).
There is currently no consensus as to whether individuals with UMMRD should
follow surveillance recommendations based on their personal/family histories of cancer or if
more stringent LS surveillance should be utilized. Decisions about surveillance for
individuals with UMMRD and their family members may therefore be at the discretion of the
physician (13). The lack of clarity surrounding surveillance recommendations for individuals
with UMMRD highlights the importance of comprehensive genetic testing for germline
MMR mutations.
The identification of underlying germline mutations in individuals who were
originally classified as having UMMRD is imperative for providing tailored screening
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guidelines to individuals and their family members. In addition, it is important that the
affected individuals themselves understand how identifying an underlying germline mutation
may change screening recommendations. If patients do not understand the potential impact of
updated genetic testing for themselves or their family members, they may fail to receive
updated genetic testing or to communicate these changes to relatives. Therefore, this study
aims to evaluate the interest in and perceived impact of further germline genetic testing
among individuals with UMMRD.
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METHODS
Study Population
The study population consisted of patients from the University of Texas MD
Anderson Cancer Center (UTMDACC) with a personal history of CRC or EC and UMMRD
due to loss of IHC staining but no presence of germline pathogenic variant upon incomplete
clinically available germline testing for LS. This included patients with variants of uncertain
significance. Full clinically available germline testing was defined as sequencing and
deletion/duplication analysis of MLH1, MSH2, MSH6, and PMS2, deletion/duplication
analysis of EPCAM, and MSH2 inversion testing. All study participants were Englishspeaking and 18 years or older. Individuals meeting the study population criteria were
identified by querying the UTMDACC genetic counseling database. Exclusion criteria
included individuals with tumors showing loss of MLH1 on IHC staining with BRAF
mutations or MLH1 promoter hypermethylation on tumor studies, thus indicating sporadic
tumors. Eligibility criteria was confirmed by evaluating patient electronic medical records.
The study was approved by the UTMDACC Institutional Review Board (PA17-0473) and the
University of Texas Health Science Center at Houston Institutional Review Board (HSC-MS17-0831).
Instrumentation
A survey containing questions about current screening behaviors, original testing
considerations, interim family histories, and the perceived impact of identification of a
germline mutation as opposed to the perceived impact of negative germline testing was
utilized (see Supplementary Material).
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Procedures
The survey and informed consent were mailed to each potential participant along with
information about the availability of updated genetic testing as part of clinical care. The
informed consent document provided consent for survey participation as well as review of
medical records. Up to three attempts were made to contact the participants regarding study
participation. Participants also had the option to complete the survey over the phone or when
approached while attending scheduled clinic visits.
An electronic health record review was completed for each participant. The
information obtained included basic demographic information, personal and family history of
cancer, dates of genetic counseling visits, tumor pathology results, and genetic testing results.
Deidentified survey responses and data collected from the electronic health record
were entered in the online survey tool RedCap. Patient data was stored on a secure server
hosted by UTMDACC.
Data Analysis
A level of p=0.05 was set for significance. Descriptive statistics were used to analyze
the data.
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RESULTS
A total of 98 patients met the eligibility criteria, of whom 31 individuals responded to
the survey (response rate of 32%). Twenty-five (81%) participants were non-Hispanic white.
Twenty-seven (87%) participants had at least some college education, and 21 (68%) had an
annual household income greater than $50,000. The average age of the study population was
62 years (range 33-81 years). The demographic characteristics of the respondents are
summarized in Table 1.
Table 1: Participant Demographics
N (%)
Ethnicitya
Non-Hispanic White
Hispanic
Asian
Other
Education
<High School
High School/GED
Associate/Bachelor
Postgraduate degree
Religionb
Christian
Do not identify
Hinduism
Annual Household Income
<$50,000
$50,000-100,000
>$100,000
Sexc
Female
Male
Average Age
a, b
Based on participant self-identification
c

25 (81)
2 (6)
1 (3)
3 (10)
1 (3)
3 (10)
10 (32)
17 (55)
29 (94)
1 (3)
1 (3)
5 (16)
8 (26)
13 (42)
19 (61)
12 (39)
62 years (range of 33-81)

Participant sex was collected from the electronic health record
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Cancer History
Twenty-one (68%) respondents had a personal history of CRC, and 10 (32%) of EC.
Nine (29%) respondents had a personal history of another cancer including breast, prostate,
skin, and stomach tumors. One of these nine respondents had a personal history of colorectal,
skin, and stomach cancers, as well as a sebaceous neoplasm. IHC results of CRC or EC were
abnormal in all 31 participants. On IHC analysis, 14 (45%) respondents had tumors with loss
of MLH1, 8 (26%) had loss of MSH2, 14 (45%) had loss of MSH6, and 13 (42%) had loss of
PMS2. Twenty (65%) respondents displayed loss of more than one protein.
Family History
The family history information gathered from the electronic health record and the
survey were compiled to determine if respondents met Amsterdam criteria for the
identification of individuals likely to have LS (10). Four (13%) respondents met Amsterdam
criteria.
Based on the family history collected from the electronic health record, 29 (94%)
respondents had a family history of some type of cancer at the time of original genetic
counseling. Of these 29 individuals, 23 (79%) had a family history of at least one Lynchrelated cancer. Of the two remaining respondents without a family history of cancer, one had
no family history of cancer at the time of genetic counseling, and the other respondent was
adopted. In an evaluation of the reported interim family history of cancer, 10 (32%)
respondents had a family history of cancer since original genetic counseling. Of these
individuals, 4 (40%) respondents had an interim family history of at least one Lynch-related
cancer, while 6 (60%) respondents had a family member diagnosed with non-LS-associated
cancer since original genetic counseling.
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Perceived Cause of EC or CRC
Respondents were asked what they believed to be the cause of their cancer (Figure 1).
Eight (26%) respondents indicated they felt there was more than one cause for their cancer.
Twenty-one respondents (68%) indicated they thought an underlying genetic mutation was at
least one reason for the development of cancer. When asked about the level of importance of
determining the cause of cancer, 27 (87%) respondents thought that it was important or
extremely important.
Figure 1

Anticiapated Cause of Cancer

Participant-Perceived Cause of EC or CRC (n=31)
Environmental
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Psychosocial Issues Surrounding Original Genetic Testing
The average time since original cancer diagnosis was 9.7 years (range = 1-35 years).
Fourteen (45%) respondents initially had genetic counseling within the last 5 years. Ten
(32%) respondents originally had genetic counseling 6-10 years prior to completion of the
survey, while 7 (23%) respondents originally had genetic counseling 11-20 years prior.
Twenty-six respondents (84%) indicated the original decision to undergo genetic testing was
either not stressful or only a little stressful.
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Respondents were asked to rank potential reasons for undergoing original genetic
testing. If participants did not feel a listed factor influenced their original genetic testing
decision, it was not ranked. Eighteen (58%) respondents indicated their primary reason for
pursuing genetic testing was concern that other family members may develop cancer as well
(Figure 2). Overall, 26 (84%) respondents indicated that concern for family members to
develop cancer factored in to their decision to undergo genetic testing, and this was the most
frequently ranked factor impacting the original genetic testing decision. The most frequently
ranked second answer was concern for an increased risk to develop another cancer related to
a genetic mutation. This factor had a bimodal distribution, with 10 participants selecting this
factor as a primary or secondary reason, and 6 participants selecting this factor as the fifth or
sixth reason they originally pursued genetic testing. Associations between concern for an
increased risk to develop another cancer and current age (p=0.79) or number of children
(p=0.37) were not statistically significant.
Figure 2
Factors Contributing to Decision to Undergo Original Genetic Testing
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Family History

Doctor

Reasons for Pursuing Original Genetic Testing
Rank Order:

1

2

3

10

4

5

6

Genetic Counselor

Psychosocial Issues Surrounding Updated Genetic Testing
Twenty-four (77%) respondents indicated they were either interested or extremely
interested in updated genetic testing. When asked about level of concern for family members
to develop cancer, 23 (74%) respondents were at least somewhat worried, with 13 (42%)
respondents indicating they were very worried that family members would develop cancer.
Respondents were asked about expected feelings if a pathogenic variant were found
on updated genetic testing compared to negative results. Seven (23%) respondents indicated
they would feel very relieved if genetic testing results indicated a pathogenic variant
consistent with LS, while 10 (32%) respondents indicated they would feel very relieved if
updated genetic testing were negative (Figure 3). In comparison, 3 (10%) respondents
indicated they would feel very worried if a pathogenic variant were found on updated genetic
testing, whereas no respondents indicated they would feel very worried if no mutation were
found. Overall, 14 (45%) respondents indicated they would feel relatively less concerned or
more relieved if a pathogenic variant were not identified on updated genetic testing. The
remainder of the respondents were divided between those who would be relatively more
worried/less relieved if no mutation were found, or their concern would not change
regardless of the result. This was not a statistically significant difference (p=0.207).
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Figure 3
Anticipated Feelings if Mutation was Identified vs. Not
Identified on Updated Genetic Testing (n=31)

Anticipated Feeling

Very worried
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When asked about concerns regarding updated genetic testing, 23 (74%) respondents
did not have any concerns, 2 (6%) respondents did have concerns, and 6 (19%) respondents
were unsure. Cited reasons for concern included the time requirements for testing, concerns
about the impacts of the results, and concerns about insurance coverage and privacy.
Genetics Knowledge
Respondents were asked questions to elicit understanding about the current genetic
testing recommendations for family members. These questions included indicating whether
respondents thought family members were recommended to pursue genetic testing and which
specific family members, if any, were recommended. In most cases, family members of
individuals with an uninformative negative result or a VUS would not be recommended to
pursue genetic testing. However, 20 (65%) participants either indicated that their family
members are currently recommended to pursue genetic testing or selected at least one family
member for whom genetic testing would be recommended. Similarly, 21 (68%) participants
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either indicated that genetic testing would be recommended or that a specific family member
would be recommended to have genetic testing if a pathogenic variant were not found on
updated genetic testing. There was not a statistically significant correlation between genetics
knowledge and time since original genetic counseling (p=0.66).
When asked if family members would be recommended to have genetic testing if a
pathogenic variant were identified on updated genetic testing, 29 (94%) respondents
indicated that genetic testing would be recommended.
Screening Behaviors
Fifteen (48%) respondents indicated they undergo colonoscopies at least annually. Of
the 19 female respondents, 14 (74%) have had a total hysterectomy and bilateral salpingooophorectomy, 3 (16%) had a hysterectomy only, and 2 (11%) had their uterus and ovaries
intact. The reasons for surgeries were not elicited. Of the 10 women who had EC, 80% had
colonoscopies at least every 2-3 years.
When asked about perceived frequency of colonoscopies if a pathogenic variant were
identified on updated genetic testing, 18 of 31 (58%) respondents indicated that they would
have colonoscopies at the same frequency, while 11 (35%) respondents thought the
frequency of colonoscopies would increase.
Interpretation of Prior IHC and Germline Testing
Medical record review indicates that original genetic testing consisted of analysis of
one gene for 13 (42%) of the respondents. Nine (29%) respondents had two of the genes
associated with LS tested upon original genetic testing. Twenty-three (74%) participants had
uninformative negative results upon original genetic testing, while 8 (26%) participants had a
variant of uncertain significance (VUS).
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Information last reported to the participants regarding their likelihood to have LS was
gathered from the medical record. Seven (23%) participants were told they have a definitive
diagnosis of LS based on IHC results. Nine (29%) participants were told they likely have LS,
while 14 (45%) participants were told it is unclear whether they have LS. One participant
was told that based on personal and family history evaluation, LS is an unlikely explanation
for the IHC results. Of the 9 participants who were told they likely have LS, 8 (89%)
perceived a genetic mutation to be an underlying cause of their EC or CRC.
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DISCUSSION
Our study aimed to evaluate the interest in and perceived impact of updated genetic
testing among patients with UMMRD. The results of the study emphasize that the primary
reason for interest in updated genetic testing among individuals with UMMRD is concern for
family members to develop cancer and desire for family members to have appropriate
screening. Providing family members with accurate information was the most frequently
stated reason for interest in updated genetic testing, as well as the most frequently stated
reason that participants felt it was important to determine the cause of their cancer. Concern
for family members to develop cancer was the most frequently selected primary reason for
originally pursuing genetic testing, and it was the most frequently selected choice overall.
Because 74% of respondents are at least somewhat worried about family members
developing cancer, it is reasonable that concern for family members was a primary factor in
originally pursuing genetic testing. This is concordant with previous studies evaluating the
motivators for pursuing original genetic testing for LS (14, 15). Therefore, our findings
suggest that the reasons for interest in updated genetic testing among this population are
similar to those indicated in the literature for original genetic testing for LS.
Participants also indicated that concern or relief for family members may impact
anticipated feelings regarding results of updated genetic testing. The effect of genetic testing
results on family members was most frequently raised in the context of feeling relief after
updated genetic testing, both if a pathogenic variant was or was not identified. Participants
indicated they would feel relief because family members could have genetic testing if a
pathogenic variant was identified, and appropriate high-risk surveillance if they were found
to be positive for the familial variant. This may indicate that a primary motivating factor for
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updated genetic testing is anticipated relief felt for family members, either in the context of
positive or negative genetic testing results. Concern for family members was not mentioned
as a possible deterrent for updated genetic testing. Instead, possible deterrents for genetic
testing included lack of information about the test, concerns about insurance coverage, time
considerations, and the possibility of an uncertain result. It may be that interest in updated
genetic testing is fueled by what is viewed as definitive information being helpful for family
members, regardless of the results.
Because participants are focused primarily on impacts of genetic testing for family
members, it may be important for clinicians to emphasize the potential implications of
updated genetic testing for participants themselves. Forty-eight percent of the participants
had at least annual colonoscopies. This points to a greatly increased screening regimen
compared to people in the general population. Women with no history of CRC who are
receiving frequent colonoscopies are having more screening than would be recommended if
they could be determined to have sporadic cancer rather than LS, for example, using paired
somatic/germline testing for the identification of biallelic somatic mutations. Therefore, the
potential impact of updated genetic testing on the personal screening recommendations for
women with UMMRD should be emphasized.
The results of this study also indicate a need for updated genetic counseling among
individuals with UMMRD. There was wide variation in participants’ anticipated feelings if a
pathogenic variant were found or not found on updated genetic testing. If updated genetic
testing were negative, many respondents who indicated they expected to feel relief suggested
their family members may be required to have less frequent screening, while respondents
who expected to feel worried indicated they would still have no information about the cause
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of the cancer. From a clinician perspective, updated negative germline testing for LS cannot
rule out LS. In the context of UMMRD and uninformative negative germline genetic testing
for LS, an updated review of family and personal medical histories as well as review of
additional testing options, both germline and somatic, is necessary to elicit screening
recommendations for family members. Therefore, updated genetic counseling with or
without updated genetic testing can provide participants with the most current information
regarding the evolving understanding of the clinical significance of MMR deficiency, as well
as the most appropriate screening recommendations.
Updated genetic counseling may also be important for clarifying genetic testing
recommendations for family members. Although most family members of individuals with
an uninformative negative result or VUS would not be recommended to undergo genetic
testing, exceptions exist including testing for research purposes or situations in which other
family members also meet criteria for genetic testing independent of the uninformative
negative genetic testing results of a family member. Ninety-four percent (29 respondents)
understood family members would be able to have testing for the familial variant if updated
genetic testing identified a pathogenic variant. However, participants were more likely to
have confusion about recommendations for family members in the context of an
uninformative negative result. This is not surprising given that the average time since original
genetic counseling was 7 years, and points to the necessity of updated genetic counseling and
risk assessment for individuals with UMMRD.
Upon original genetic testing, 8 participants had a VUS. Because implications of
genetic testing results are especially nuanced for family members of patients with a VUS on
original genetic testing, updated genetic counseling may be especially important for this
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subgroup of participants. Three of these 8 individuals met Amsterdam criteria based on an
analysis of the original family history reported at the time of original genetic counseling and
an analysis of the interim family history reported on the patient survey. Given the strong
personal and family histories of cancer in these three families, their VUS could potentially
represent pathogenic mutations. Updated genetic counseling should include a reevaluation of
these variants for potential updates in classification.
Perhaps the most important reason for updated genetic counseling in this population
is to provide updates about clinician understanding of potential causes of MMR deficiency.
Until approximately 2014, the primary cause of tumor defects in the MMR pathway (other
than MLH1 promoter hypermethylation or BRAF V600E mutation) was thought to be LS, and
patients were often counseled that they likely had LS even in the absence of a pathogenic
variant on germline testing. The changing understanding of the contribution of biallelic
somatic mutations as an etiology of UMMRD and the advent of paired somatic/germline
genetic testing may require re-contacting patients with UMMRD, even those who previously
had comprehensive germline genetic testing. While our study does not evaluate patient
interest in paired germline/tumor testing, this exploration of the interest toward germline
genetic testing among patients with UMMRD allows for a better understanding of the
psychosocial concerns of these patients, which is critical at a time when paired
germline/tumor testing is entering the genetic testing landscape. Previous studies have shown
that patients believe it is important to know about updates in available genetic testing for
other cancer types, but the most effective method for notifying patients about updated genetic
testing remains unclear (16). This area of study may be critical for this patient population as
paired somatic/germline genetic testing is adopted.
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The participants who did not meet Amsterdam criteria may have other explanations
for MMR defects in their tumors. While 45-69% of patients with UMMRD are expected to
have biallelic somatic mutations causing MMR deficiency (6, 9), 68% percent of respondents
perceived at least one cause of their cancer to be an underlying mutation. This is higher than
previous estimates of expectations of individuals with CRC to carry a mutation causing
cancer (14). It is possible that this is due to differences in original counseling, as individuals
with UMMRD have a higher risk of having LS compared to the general population of those
with CRC. However, it is unlikely that all the participants who perceive that an underlying
pathogenic mutation caused their cancer truly have LS. Therefore, updated genetic
counseling and risk assessment is critical for this population to provide information about
best screening practices, as well as to potentially provide reassurance that LS is not the sole
explanation for UMMRD.
Study Limitations
Our population was overall highly-educated, with a non-Hispanic white background
and an average age of 62-years-old. It is not clear if the results of the study can be
extrapolated to individuals of a lower socioeconomic status or younger individuals who may
have different perceptions of their personal cancer risks. Our population was subject to
selection bias, as individuals interested in updated genetic testing may be more likely to
respond to a survey on this subject. Our study is limited by a low response rate and low
statistical power. Although UTMDACC is a large tertiary care center with an extensive
patient database, only 98 individuals met eligibility criteria. This reflects the specificity
required to meet the eligibility criteria.
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Practice Implications
This patient population is extremely interested in updated genetic testing, with the
primary reason being the potential impact of updated genetic testing on family members. An
understanding of the psychosocial concerns of this population can help clinicians validate
these concerns while also emphasizing the importance of updated genetic testing for the
patients themselves. For individuals who received genetic counseling years ago, a discussion
of other potential causes of MMR deficiency as well as an updated risk assessment and
discussion of screening recommendations will provide patients with the most up-to-date
information. While a formal updated genetic counseling session for all patients with
UMMRD may not be possible in the context of a busy clinic, a counselor-based effort to
reestablish contact with this population may be helpful in initiating a conversation with those
who are interested in an updated risk assessment.
Research Recommendations
Because our population was primarily highly educated and non-Hispanic white,
further research is necessary to elucidate if similar concerns are prevalent across other
socioeconomic backgrounds. A cross-institutional study of individuals with UMMRD will
also provide adequate statistical power to establish factors that contribute to interest or lack
of interest in updated genetic testing. Such a study will also provide the opportunity to further
investigate subgroups of interest, including those who fulfill Amsterdam criteria and those
with a VUS upon original genetic testing. Additionally, a survey of patient attitudes toward
somatic MMR testing is necessary as paired tumor/germline testing becomes an important
component of the genetic testing landscape. Furthermore, a study regarding the uptake of
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updated genetic counseling and results of updated genetic testing may provide more
information about this population.
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APPENDIX
Title: Patient Perceptions of Germline Mutation Findings in People with Unexplained
Mismatch Repair Deficiency
Survey
You are receiving this survey because you were evaluated for Lynch syndrome based on
previous testing on your colorectal or endometrial tumor. Lynch syndrome is a genetic
condition that leads to an increased risk for colorectal, uterine (endometrial), and other
cancers. You had genetic testing for Lynch syndrome, but results came back negative. This
means we did not find a genetic change that explained why you developed cancer. You have
received a letter explaining that there is now updated genetic testing available to you.
The following survey aims to evaluate your views and opinions about additional testing to
determine if you have Lynch syndrome. If you decide to take part in the study, your total
time commitment is estimated to be 15 minutes. You can refuse to answer any questions
asked or written on any forms. Participation in this study is voluntary. A decision not to take
part in this study will not change the services you receive through MD Anderson Cancer
Center.
Please answer the following questions as completely as possible:
Demographics
1. With which ethnicity do you identify?
 Black
 Caucasian
 Hispanic
 Asian
 Other (please specify):
2. What is the highest level of education that you have completed?
 Did not finish high school
 High school/Equivalent
 Associate’s degree (2 years of college)
 Bachelor’s degree (4 years of college)
 Master’s degree/PhD/Professional degree (MD, JD)
 Trade school
 Other (please specify):
3. How many biological children do you have?
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4. With which religious belief system do you identify?
 Christian
 Muslim
 Judaism
 I do not identify with a religion
 Other: (please specify)
5. Do you have health insurance from a private company (such as Cigna, BlueCross
BlueShield) or from a public source (such as Medicare or Medicaid)? Please circle one
option below.
PUBLIC INSURANCE
INSURANCE

PRIVATE INSURANCE

I DON’T HAVE

6. What is your total annual household income before taxes?







Less than $10,000 per year
$10,000-$24,999 per year
$25,000-$49,999 per year
$50,000-$74,999 per year
$75,000-$99,999 per year
Greater than $100,000 per year

Family History
7. Since the time that you originally had genetic counseling and genetic testing, have any
biological family members (parents, siblings, children, aunts/uncles, grandparents,
cousins) been diagnosed with cancer? If so, please list them below including the
relationship to you, the type of cancer, and the age of the family member when he/she
was diagnosed.
Family Member
Example: Brother

Type of Cancer
Colon Cancer
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Age at Diagnosis
56

If you do not have any family members who have been diagnosed with cancer since the time
of your original genetic counseling, please check here: _______
Previous Genetic Testing
8. What do you think caused your cancer? Please check all that apply.







Environmental exposures
Genetic mutation
Life stressors
Smoking
Diet/weight
Other (please explain):

9. What was your original reason for pursuing genetic testing for Lynch syndrome?
Please rank the following reasons, with “1” being the most important reason to you. If
any of the reasons do not apply, please write “N/A.”
____
____
___
____
____
____
____

I was worried about getting cancer again
I was worried about my family members getting cancer
To determine the best treatment or screening regimen
My family history of cancer
My doctor told me to
My genetic counselor told me to
Other (please explain):

10. How stressful or worrisome was it for you to decide to have genetic testing for Lynch
syndrome originally?
1
Not stressful

2
A little stressful

3
Neutral

Please explain:
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4
Stressful

5
Extremely Stressful

11. How important to you is it to find out what caused your cancer?
1
Not important

2

3

A little important

Neutral

4
Important

5
Extremely Important

Please explain:

12. We have not currently found a genetic change that explains why you developed
cancer. Based on your negative test results, do you think your family members would
currently be recommended to pursue genetic testing?

YES

NO

12a. If so, for which living family members do you think genetic testing would
currently be recommended?









Parents
Siblings
Children
Aunts/Uncles
Nieces/Nephews
Cousins
Grandparents
Other:

13. Have any of your family members already undergone genetic testing for a hereditary
cancer syndrome?

YES

NO

I DON’T KNOW

13a. If so, what is this person’s relationship to you, and what were the results of the
test?
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14. Based on your history of cancer, do you think any of your family members currently
wish to pursue genetic testing?

YES

NO

I DON’T KNOW

Comments:

15. How concerned are you that your family members may also get cancer?

1

2

3

4

Not worried
Worried

A little worried

Somewhat Worried

Moderately Worried

Comments:

16. How frequently do you receive colonoscopies?







Multiple times a year
Once a year
Every 2-3 years
Every 4-5 years
Every 6-10 years
Never

17. Do you have any other regular screening to check for cancer?
 Mammogram/breast exam
 Prostate cancer blood test
 Ovarian cancer blood test
 Upper endoscopy
 Other:
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5
Very

Updated Genetic Testing
18. Updated genetic testing is available to you. Are you interested in pursuing further
genetic testing that could identify a cause for your cancer?
1

2

Not interested

A little interested

3

4

Neutral

Interested

5
Extremely Interested

If interested, why? If not interested, why not?

19. How would you feel if a genetic mutation were found in the updated testing?

1

2

Very worried

Somewhat Worried

3

4

Neutral

Somewhat Relieved

5
Very relieved

Comments:

20. If you were found to have a mutation that explained your cancer, with whom would
you share this information? Check all that apply








Spouse/partner
Family: parents, siblings, children, etc.
Friends
Healthcare provider
A spiritual leader
A support group
Other (please list):
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21. How do you think you would feel if no genetic mutation were found in the updated
testing?

1
Very worried

2
Somewhat Worried

3

4

Neutral

Somewhat Relieved

5
Very relieved

Comments:

22. If a mutation was found that predisposed you to develop cancer, do you think your
family members would be recommended to pursue genetic testing for a predisposition
to develop cancer?
YES

NO

22a. Based on these test results, to which family members do you think genetic
testing for a predisposition to develop cancer would be recommended?









Parents
Siblings
Children
Aunts/Uncles
Nieces/Nephews
Cousins
Other:
None of my relatives

23. If no mutation was found that predisposed you to develop cancer, do you think your
family members would be recommended to pursue genetic testing for a predisposition
to develop cancer?
YES

NO
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23a. Based on these test results, to which family members do you think genetic
testing for a predisposition to develop cancer would be recommended?









Parents
Siblings
Children
Aunts/Uncles
Nieces/Nephews
Cousins
Other:
None of my relatives

24. How do you think your colonoscopy screening would be different if we found a
mutation that caused your colorectal cancer?
 More frequent colonoscopies
 Same number of colonoscopies
 Less frequent colonoscopies

25. If a mutation were found that explained why you developed cancer, what other types
of screening do you think would be recommended? Check all that apply.
 Skin exam
 Mammogram/breast exam
 Prostate cancer blood test
 Ovarian cancer blood test
 Upper endoscopy
 Other:

26. Do you have any concerns about pursuing further genetic testing?

YES

NO

a. If so, what are they?
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UNSURE
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